Function of mambalgin 1 in inhibiting acid-sensing ion channels

2024-07-09

Introduction 

Mambalgin 1, a toxin isolated from black mamba venom, is a disulfide-rich polypeptide consisting of 57 amino acids and belongs to the family of three-finger toxins. It is an effective, rapid, reversible inhibitor of ASIC1a or ASIC1b-containing channels in both central and peripheral neurons. The analgesic effect of mambalgin 1 is as strong as that of morphine, but it does not involve opioid receptors. Compared with traditional opioid drugs, it has fewer side effects and has higher therapeutic value.

Pharmacologic action

The X-ray structure of mambalgin-1 has been solved and consists of a three-finger protein fold in which typically three "finger-like" loops containing beta folds are emitted from a central core stabilized by disulfide bonds.. Structurally, mambalgin 1 is directly integrated with the thumb area of cASIC1a. Mambalgin 1 interacts only with the outer surface of the thumb area of cASIC1a, rather than with an acidic pocket, or with the proposed interfacial region in the beta-ball or palm field. A detailed interface analysis showed that Finger I of mambalgin 1 interact with the α4 helix of the cASIC1a thumb domain. The cassi1a mutants (r316A and y317a) located on the α4 helix also showed different inhibitory responses to manbalgin 1 binding.

Function

Asics is involved in a variety of physiological processes, including synaptic plasticity, neurodegeneration, and pain. As a result, Asics has become a new potential therapeutic target for the treatment of mental illness, neurodegenerative diseases and pain. Mambalgin 1 interacts directly with the thumb domain of cASIC1a but not with the acid-sensing pocket as hypothesized through docking analysis based on cASIC1a–PcTx1 crystal structures. At the same time, mambalgin 1 binding was observed to induce an obvious conformational change in the extracellular thumb domain of cASIC1a, which might disrupt the acid-sensing process in cASIC1a.

Pharmacokinetics and metabolism

Mambalgin 1 has undergone clinical trials and has developed venom-based drugs that inhibit neural pathways involved in pain and other sensory pathways. In laboratory experiments using laboratory mice, mambalgin 1 appears to exert clinically significant analgesic effects without side effects (such as respiratory depression and drug tolerance, both associated with opioid analgesics) typically associated with opioid analgesics.

References:

1. Wemmie, J. A., Taugher, R. J., & Kreple, C. J. (2013). Acid-sensing ion channels in pain and disease. Nature Reviews Neuroscience, 14(7), 461-471.

Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!

  Etomidate, a highly selective intravenous anesthetic agent, was first synthesized at Janssen Pharmaceuticals in ...

In the respiratory tract, there are tachykinin P (SP) and neurokinin A (NKA) in capsaicin-sensitive primary affe ...

 MEN 11270 (H-DArg-Arg-Pro-Hyp-Gly-Thi-c(Dab-Dtic-Oic-Arg)c(7γ-10α)) is a novel selective constrained peptide ant ...

Palmitoyl Tripeptide-1 is also called Part of Matrixyl 3000. Palmitoyl Oligopeptide and Pal-GHK are believed to be able to st ...

Background Aclerastide, one angiotensin receptor agonist, is the active ingredient of DSC127 and its general structure is sho ...

Contact Us

USA

Address:

Tel: |

Email:

Germany

Address:

Copyright © 2024 Creative Peptides. All rights reserved.